Q2i Reports Significant Milestone in California’s Statewide Contingency Management Program for Stimulant Use Treatment
Boston, MA – 11 March 2025
Q2i today announced its pivotal role in the successful rollout of the Recovery Incentives Program: California’s Contingency Management benefit for stimulant use disorder treatment. Powered by Q2i’s advanced State Incentive Management System (SIMS), the program has reached a major milestone, providing treatment access to more than 5,000 Medi-Cal (California’s Medicaid program) members across the state.
There are no pharmacological treatments for stimulant use disorder. Contingency management is one of the few evidence-based practices that has been shown to be effective for treating stimulant use. In fact, contingency management has the strongest base for treating stimulant use disorder. Despite its proven effectiveness, contingency management programs have faced challenges in the past, including intensive administrative oversight and logistical complexity.
California’s Recovery Incentives Program, supported by Q2i’s SIMS platform, addresses these barriers. SIMS automates key functions, such as secure incentive management, real-time reward distribution, and fidelity monitoring. This streamlined approach reduces administrative demands, improves efficiency, and delivers actionable insights to enhance clinical outcomes.
“We are pleased with the success of our statewide Recovery Incentives Program,” said Ivan Bhardwaj, Medi-Cal Behavioral Health Policy Division Chief for the California Department of Health Care Services (DHCS). “Q2i’s technology has been instrumental in ensuring seamless program logistics, immediate reward distribution, and measurable reductions in stimulant use. Thousands of Californians have benefited from this transformative approach.”
Bhardwaj continued, “California is proud to be the first state in the nation to include contingency management as a Medicaid benefit. Contingency management is the only evidence-based practice for stimulant use disorder that has been demonstrated to reliably produce positive treatment results, including reduction or cessation of stimulant use and longer retention in treatment. This innovative program reflects our commitment to improving public health and fostering recovery.”
Steven Jenkins, CEO of Q2i, added, “The SIMS platform, developed through a research grant from the National Institutes of Health, empowers providers and participants alike. By automating incentive delivery and tracking milestones in real time, we’ve made recovery more accessible and impactful for thousands of individuals.”
About Q2i:
Q2i is a privately held digital health company specializing in the development, refinement, validation, and commercialization of evidence-based, innovative solutions. Our technologies enhance clinical care, increase engagement, and improve outcomes.
As global leaders in technology-driven contingency management solutions, Q2i is driving health care innovation. Our business division, Contingency Management Innovations, is the world’s leading developer of AI-powered contingency management technology, transforming behavior reinforcement and clinical outcomes.
For more information, visit: